Listen to this article · 7 min listen

When you’re tracking companies in something like the AI Health 100, the success stories are always front and center. But the real work of a good alumni tracker is documenting every single outcome, including the spectacular flameouts. A company’s journey, even one that ends in bankruptcy court, leaves behind a paper trail of data and industry recognition that we can all still learn from. Understanding the difference between a rumor of failure and a hard, documented failure record is how you get a real grasp of where AI in healthcare is actually going.

The Enduring Value of a Documented Alumni Record

An alumni tracker for a fast-moving field like AI health has to keep a complete history of every company it lists. That means following them from their early days through maturity, noting their awards and watching their growth. It’s more than just a scoreboard. The tracker is a historical record that preserves what happened to each company and why. When a business that was once a big name goes under, its file doesn’t just get deleted. It becomes a case study for anyone trying to understand market traps, regulatory nightmares, and commercial dead ends. All the material on these companies, from their revenue charts to their press clippings, stays right there for you to inspect.

What a Bankrupt/Failed Record Still Reveals

Seeing a “Bankrupt/Failed” tag on a company profile isn’t just an endpoint. For a sharp investor, it’s the starting gun for some serious research. Take Pear Therapeutics, which ended up in bankruptcy. The company’s fall from a $1.6 billion valuation to having its assets sold off for a mere $6.05 million is a brutal lesson about the digital health business Fierce Healthcare report on Pear Therapeutics bankruptcy. That collapse, mostly because they couldn’t get anyone to pay for their product, shows the huge gap between getting FDA clearance and actually building a sustainable business. The tracker preserves this record, showing that regulatory approval doesn’t mean market acceptance or a viable company. It’s a critical piece of data for anyone weighing the risks in similar startups, and it proves that even pioneers can fail if they can’t figure out a reimbursement strategy.

Connecting the Alumni Thread: Pear Therapeutics, Akili Interactive, and Tempus AI

The AI Health 100 alumni tracker puts Pear Therapeutics in the same frame as Akili Interactive and Tempus AI because they share a history in the index. Each of these vendors earned significant recognition and left a documented trail in the AI health story. The data signals for this group are “Bankrupt/Failed,” “Revenue Growth,” and “STAT Medicine 50” recognition. While Pear’s record has that “Bankrupt/Failed” signal, the fact that all three have signals for revenue growth and industry awards gives you a much richer picture of their paths. Discussions about digital health value destruction often bring up Pear Therapeutics and its $1.6 billion peak valuation before it went bankrupt Digital Health Value Destruction analysis, which puts Pear’s crash into the context of massive capital losses across the sector. Akili Interactive’s story is different but it operated in the same tough environment where, as Pear’s experience taught many, FDA clearance doesn’t guarantee commercial success Analysis of FDA clearance without reimbursement challenges. After hitting its own commercialization walls, Akili Interactive was bought by Virtual Therapeutics for about $34 million in 2024 and taken private. Tempus AI, the third member of this group, often comes up in conversations about which companies are doing real AI versus just marketing basic tech Critique of AI marketing versus reality in healthcare. Tempus AI went public on the Nasdaq in June 2024 and has posted strong revenue growth, reporting $382.5 million for Q2 2026. The point is, no matter how they ended up, these companies all produced verifiable publications and received recognition that any investor can still pull up and examine today.

The Instructive Read: Beyond the Failure Story

The real lesson from a failed company like Pear Therapeutics is that its revenue history and publication record will outlive the business itself. That record is still in the tracker because the source material is still out there and verifiable. This separation between a fleeting story about failure and a durable, documented record of it is what matters. Investors can independently trace the signals (the bankruptcy status, the revenue growth patterns, the STAT Medicine 50 award) without having to talk to a vendor or rely on their marketing spin. This objective, document-first method makes for much better due diligence. The story of Pear Therapeutics, a pioneer in prescription digital therapeutics, is laid out in incredible detail through its SEC filings and industry reports, from its $1.6 billion peak valuation to the final $6.05 million asset sale SEC filings and Fierce Healthcare on Pear Therapeutics. These detailed records create a verifiable timeline of the capital raised and the market valuation, and they offer hard lessons on market adoption and reimbursement. Because these records don’t disappear, investors can pick apart the factors that led to both the initial hype and the eventual collapse, which helps inform where they put their money next.

What Investors Can Verify Independently

If you’re an investor using the AI Health 100 to study company outcomes, you have to be able to check claims and track histories on your own. The documented records for companies like Pear Therapeutics, Akili Interactive, and Tempus AI are a goldmine for this. You can go directly to public sources to see their FDA clearances, read the financial filings that show their revenue, and find their recognition in reputable publications like STAT News. This is all hard evidence of a company’s journey. The “Bankrupt/Failed” record for Pear, for example, isn’t gossip. It’s backed by court proceedings and financial reports detailing the asset sales. Likewise, you can cross-reference any revenue claims from Akili Interactive or Tempus AI with their public statements and scientific publications. Sticking to documented, verifiable facts is what makes the AI Health 100 alumni tracker a trustworthy resource, giving you a clear, evidence-based view of who’s winning and who’s losing in AI health.

Frequently Asked Questions

How does the AI Health 100 alumni tracker define ‘failure’ and what information does it provide for such cases?

The AI Health 100 alumni tracker uses the designation ‘Bankrupt/Failed’ to indicate a company’s cessation of operations. This record is not merely a final status update but a signal that unlocks information for investors, transforming the company’s journey into a case study. It includes insights into market dynamics, regulatory hurdles, and commercial viability, with material like revenue growth or industry recognition remaining accessible and instructive.

What specific lessons can investors learn from the failure of Pear Therapeutics, as documented in the AI Health 100 alumni tracker?

Pear Therapeutics’ journey from a $1.6 billion peak valuation to assets sold for $6.05 million highlights the challenges in the digital health sector, largely attributed to reimbursement failure. This case demonstrates that FDA clearance alone does not guarantee market acceptance or financial viability, underscoring the critical chasm between regulatory approval and sustainable commercial success due to complexities of payer adoption for prescription digital therapeutics. Its record provides vital data for evaluating risk in similar ventures.

How does the AI Health 100 alumni tracker connect companies like Pear Therapeutics, Akili Interactive, and Tempus AI, and what insights can be gained from this connection?

The tracker connects these companies through a shared alumni thread, documenting their recognition and presence in the AI health narrative with signals like ‘Bankrupt/Failed,’ ‘Revenue Growth,’ and ‘STAT Medicine 50’ recognition. This collective view offers a multifaceted perspective on their journeys, illustrating that even pioneering efforts can falter without robust reimbursement (Pear), that FDA clearance doesn’t guarantee commercial triumph (Akili), and that strong revenue growth is achievable (Tempus), all within the same ecosystem.

Beyond a simple ‘failure story,’ what enduring value does a documented record of a failed company like Pear Therapeutics offer to investors?

A documented record of a failed entry like Pear Therapeutics offers an enduring ‘failure record’ because its revenue record and publication trail outlast the company itself. This allows investors to independently follow documented signals such as Bankrupt/Failed status, reported revenue growth patterns, and recognition without needing direct vendor conversations or relying on current marketing claims. This objective, document-first approach enables more rigorous due diligence.